Last reviewed · How we verify
Botulinum toxin type A infiltrations
Botulinum toxin type A blocks acetylcholine release at the neuromuscular junction, causing temporary muscle paralysis.
Botulinum toxin type A blocks acetylcholine release at the neuromuscular junction, causing temporary muscle paralysis. Used for Chronic migraine, Cervical dystonia, Blepharospasm.
At a glance
| Generic name | Botulinum toxin type A infiltrations |
|---|---|
| Sponsor | Aránzazu Vázquez Doce |
| Drug class | Neurotoxin |
| Target | SNARE complex (synaptobrevin/VAMP) |
| Modality | Small molecule |
| Therapeutic area | Neurology, Dermatology, Pain Management |
| Phase | Phase 3 |
Mechanism of action
Botulinum toxin type A cleaves SNARE proteins required for acetylcholine vesicle fusion and release at the presynaptic terminal. This results in flaccid paralysis of the injected muscle that typically lasts 3-4 months. The infiltration route delivers the toxin directly into target muscles for localized therapeutic effect.
Approved indications
- Chronic migraine
- Cervical dystonia
- Blepharospasm
- Spasticity
- Hyperhidrosis
- Cosmetic wrinkles
Common side effects
- Injection site pain or bruising
- Headache
- Muscle weakness
- Neck pain
- Flu-like symptoms
Key clinical trials
- Effect of Botulinum Toxin Type A on Motor Function in Children With Cerebral Palsy (NA)
- Botulinum Toxin for Chronic Neuropathic Pain
- Botulinum Toxin in Patients With Spastic Lower Limb Paresis Associated With Multiple Sclerosis (PHASE3)
- Valuation of the Evolution of Passive Mobility in the Spastic Upper Limb After Injection of Abobotulinumtoxin(Dysport®)
- Management of Popeye Sign With Botulinum Toxin After Bicepstenotomy (PHASE4)
- Therapeutic Effect of Botulinum Toxin A for the Treatment of Plantar Fasciitis. (PHASE1)
- Discomfort and Psychosocial Difficulties in Fibromyalgia (PHASE4)
- Application of Botulinum Toxin Type A in Salivary Glands in the Treatment of Drooling in Patients With Cerebral Palsy (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |